Publication | Closed Access

Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors

MedicineImmunologyAdvanced Solid TumorsImmune Checkpoint InhibitorAntibody EngineeringCancer TreatmentImmunotherapyOncologyRadiation OncologyCancer ResearchJapanese Patients